Management of recurrent ovarian cancer

Authors: M. Tkáčováihash2 1,2 1,2
Authors‘ workplace: Onkologický ústav sv. Alžbety, a. s., Bratislava, Slovenská republika 1;  I. onkologická klinika, LF UK a UN Bratislava, Slovenská republika 2
Published in: Prakt Gyn 2011; 15(3-4): 192-195
Category: Review Article


Up to 70% of patients with advanced ovarian cancer experience disease relapse after a primary treatment. Treatment of recurrent ovarian cancer is not curative. New cytostatics and treatment regimes improve efficacy of the second line therapies and thus ovarian cancer becomes a chronic disease. Surgical management with a complete resection of macroscopic disease should be considered as part of the treatment strategy for a relapsing disease. Positive response with respect to the quality of life and improved overall survival of patients with recurrent ovarian cancer may be achieved with a combination of cytoreductive surgery and systemic treatment.

Key words:
ovarian cancer – relapse – secondary cytoreduction


1. Armstrong D. Ovaries and fallopian tubes. In: Abeloff MD et al (eds). Abeloff’s Clinical Oncology. 4th ed. Philadelphia: Churchill Livingstone Elsevier 2008: 1827–1856.

2. Heľpianska L et al. Karcinóm ovária. Bratislava 2006: 12–15, 31–37, 63–77, 94–113.

3. Gertig D, Hunter D. Ovarian cancer. In: Adami HO, Hunter D, Trichopoulos D (eds). Textbook of cancer epidemiology. New York: Oxford University Press 2002: 378–399.

4. Safaei Diba C, Pleško I, Obšitniková A et al. Incidencia zhubných nádorov v Slovenskej republike 2005, Národný onkologický register SR. NCZI 2009.

5. National Comprehensive Cancer Network. NCCN Guidelines. Available from:

6. Epithelial ovarian carcinoma. In: DiSaia PJ, Creasman WT (eds). Clinical Gynecologic Oncology. 7th ed. Philadelphia: Mosby Elsevier 2007: 313–395.

7. Leitao MM Jr, Chi DS. Surgical management of recurrent ovarian cancer. Semin Oncol 2009; 36(2): 106–109.

8. Relapsed/Refractory ovarian cancer: Decision points in diagnosis and new treatment strategies (CD-ROM). Clinical care options, LLC, 2006.

9. Available from:

10. Bukowski RM, Ozols RF, Markman M. The managment of recurrent ovarian cancer. Semin Oncol 2007; 34 (2 Suppl 2): S1–S15.

11. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP-OVAR trial. Ann Surg Oncol 2006; 13(12): 1702–1710.

12. Harter P et al. Selection of the right patients for surgery in recurrent ovarian cancer. 7th European Congress: Perspectives in Gynecologic Oncology Barcelona 2010.

13. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2010; 22(1): 39–48.

14. Sehouli J, Alfaro V, González-Martín A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future. Ann Oncol 2011; 6: 1–7.

15. Lorusso D, Di Stefano A, Fanfani F et al. Role of gemcitabine in ovarian cancer treatment. Ann Oncol 2006; 17 (Suppl 5): v188–v194.

16. Wright JD, Hagemann A, Rader JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006; 107(1): 83–89.

17. Leary A, Gore M. Incorporating Bevacizumab into ovarian cancer treatment: Practical consideration. ASCO: Educational book 2011: 198–203.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account